Changes in Hong Kong stocks | Junshi Biotech (01877) rose by more than 5%, and the phase III clinical trial of treprilizumab subcutaneous injection reached the main end point and plans to apply for listing

The Zhitong Finance App learned that Junshi Biotech (01877) rose by more than 5%. As of press release, it had risen 4.43% to HK$25.48, with a turnover of HK$46.147,700.

According to the news, Junshi Biotech announced that the multi-center, open, randomized controlled phase III clinical study of treprilizumab injection (subcutaneous injection) (product code: js001sc) combined with bitriplimab injection (product code: JS001) combined with chemotherapy on the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) has reached the main study end point. Junshi Biotech plans to submit a marketing license application for this product to the regulatory authorities in the near future.

According to public information, Js001sc is a subcutaneous injection preparation developed by the company on the basis of the marketed product treprilizumab injection. It is the first domestically produced anti-PD-1 monoclonal antibody subcutaneous preparation to enter phase III clinical research, and is expected to bring convenience to patients.